BR112023022567A2 - Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos - Google Patents

Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos

Info

Publication number
BR112023022567A2
BR112023022567A2 BR112023022567A BR112023022567A BR112023022567A2 BR 112023022567 A2 BR112023022567 A2 BR 112023022567A2 BR 112023022567 A BR112023022567 A BR 112023022567A BR 112023022567 A BR112023022567 A BR 112023022567A BR 112023022567 A2 BR112023022567 A2 BR 112023022567A2
Authority
BR
Brazil
Prior art keywords
activity
compounds
small molecule
glicocerebrosidase
molecule modulators
Prior art date
Application number
BR112023022567A
Other languages
English (en)
Portuguese (pt)
Inventor
Jianbin Zheng
Kevin Hunt
Original Assignee
Vanqua Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanqua Bio Inc filed Critical Vanqua Bio Inc
Publication of BR112023022567A2 publication Critical patent/BR112023022567A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112023022567A 2021-04-30 2022-04-28 Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos BR112023022567A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163182734P 2021-04-30 2021-04-30
PCT/US2022/026676 WO2022232360A1 (en) 2021-04-30 2022-04-28 Small molecule modulators of glucocerebrosidase activity and uses thereof

Publications (1)

Publication Number Publication Date
BR112023022567A2 true BR112023022567A2 (pt) 2024-02-06

Family

ID=83848814

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022567A BR112023022567A2 (pt) 2021-04-30 2022-04-28 Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos

Country Status (10)

Country Link
US (1) US20240246952A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329880A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517789A (cg-RX-API-DMAC7.html)
KR (1) KR20240016286A (cg-RX-API-DMAC7.html)
CN (1) CN117751114A (cg-RX-API-DMAC7.html)
AU (1) AU2022267285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022567A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218510A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012853A (cg-RX-API-DMAC7.html)
WO (1) WO2022232360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820204B (zh) * 2023-12-29 2026-07-24 山东百诺医药股份有限公司 R-3-苄基-3-哌啶甲酰三甲肼的制备方法
WO2025237303A1 (zh) * 2024-05-14 2025-11-20 先声药业有限公司 β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CA2507348C (en) * 2004-05-13 2013-07-16 The Hospital For Sick Children Real time methylumbelliferone-based assay
EP2350067A2 (en) * 2008-10-16 2011-08-03 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
US8354403B2 (en) * 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
RU2015147509A (ru) * 2009-10-19 2019-01-14 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
JP2016520532A (ja) * 2013-03-15 2016-07-14 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ベンゾイミダゾール誘導体およびその使用
JP2017502961A (ja) * 2013-12-23 2017-01-26 アレクトス セラピューティックス インコーポレイテッド グルコセレブロシダーゼモジュレーターおよびその使用
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
EP3661919A4 (en) * 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
EP4039685A1 (en) * 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors

Also Published As

Publication number Publication date
MX2023012853A (es) 2024-01-12
CN117751114A (zh) 2024-03-22
JP2024517789A (ja) 2024-04-23
WO2022232360A1 (en) 2022-11-03
AU2022267285A1 (en) 2023-11-09
EP4329880A1 (en) 2024-03-06
EP4329880A4 (en) 2025-03-05
KR20240016286A (ko) 2024-02-06
CA3218510A1 (en) 2022-11-03
US20240246952A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
BR112023022524A2 (pt) Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos
BR112023015527A2 (pt) Inibidores de cdk e métodos de uso destes
BR112022018667A2 (pt) Composições e métodos para inibir a expressão de ang-ptl3
BR112022002683A2 (pt) Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos
BR112023001957A2 (pt) Composições e métodos para inibir expressão de lpa
BR112021017430A2 (pt) Inibidores da proteína tirosina fosfatase e métodos de uso dos mesmos
MX2024004581A (es) Moduladores de micromoleculas de la actividad de la glucocerebrosidasa y usos de estos.
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
BR112023016590A2 (pt) Inibidores de tyk2 e seus usos
BR112019019193A2 (pt) compostos de pirimidinil-piridilóxi-naftila e métodos para tratar de doenças e distúrbios relativos a ire-1
BR112021019880A2 (pt) Terapias gênicas para distúrbios lisossomais
BR112022012033A2 (pt) Antagonistas do receptor de melanocortina subtipo-2 (mc2r) de piperidina gem-dissubstituída e seus usos
BRPI0410963B8 (pt) anticorpo que especificamente se liga a uma região no fator de crescimento do tecido conjuntivo humano, anticorpo quimérico, composição farmacêutica, uso de um anticorpo, par de polinucleotídeos, polinucleotídeo recombinante, e, microrganismo
BR112023006024A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
ES2131525T3 (es) Usos terapeuticos de la melanina.
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
MA29931B1 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
CO2024013744A2 (es) Moduladores de nlrp3
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BR112023016678A2 (pt) Inibidores de tyk2 e usos dos mesmos
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
CO2022014499A2 (es) Moduladores de nlrp3
BR112021014566A2 (pt) Moduladores de gpr35
BRPI0510665A (pt) 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas